Additionally, silibinin-treated samples showed significant inhibition of STAT5/PD-L1 binding (Figure 6D), clearly suggesting the role of the STAT5/PD-L1 signaling cascade in the anticancer activity of silibinin against NSCLC cells that could suggest silibinin as an immunotherapeutic drug against lung cancer cells. This evidence concerns the gene STAT5B and lung carcinoma.